MIRA Pharmaceuticals, Inc. Company Profile

Background

Company Overview

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company specializing in neuroscience. Established in 2020, the company focuses on innovative treatments for a range of neurologic and neuropsychiatric disorders. Its mission is to develop novel therapies that address unmet medical needs in these areas. MIRA Pharmaceuticals is headquartered in Miami, Florida.

Mission and Vision

MIRA Pharmaceuticals aims to revolutionize the treatment landscape for neurological and psychiatric conditions by developing cutting-edge therapies that offer rapid and sustained relief to patients. The company's vision is to become a leader in neuroscience by bringing transformative treatments to market.

Industry Significance

Operating within the pharmaceutical industry, MIRA Pharmaceuticals contributes to the advancement of treatments for complex and often underserved conditions, thereby enhancing patient outcomes and quality of life.

Key Strategic Focus

Core Objectives

MIRA Pharmaceuticals is dedicated to advancing its pipeline of novel therapies through rigorous clinical development, aiming to address significant gaps in the treatment of neurological and psychiatric disorders.

Areas of Specialization

The company specializes in developing oral formulations of existing compounds, such as ketamine analogs, to provide rapid therapeutic effects with improved safety profiles.

Key Technologies Utilized

MIRA Pharmaceuticals employs proprietary drug development technologies, including advanced pharmacokinetic modeling and formulation techniques, to optimize the efficacy and safety of its therapeutic candidates.

Primary Markets Targeted

The company's primary markets include the United States, Canada, and Mexico, focusing on patients suffering from treatment-resistant depression, major depressive disorder with suicidal ideation, post-traumatic stress disorder, and anxiety-related cognitive decline.

Financials and Funding

Funding History

MIRA Pharmaceuticals has engaged in multiple funding rounds to support its clinical development programs. The company has utilized at-the-market (ATM) offerings to raise capital, resulting in the issuance of additional shares and potential dilution of existing shareholders.

Total Funds Raised

Specific details regarding the total funds raised by MIRA Pharmaceuticals are not publicly disclosed.

Recent Funding Rounds

The company has conducted at-the-market offerings, selling shares of its common stock to raise capital for ongoing operations and development activities. These offerings have been executed under agreements with financial institutions, allowing MIRA Pharmaceuticals to access necessary funds while managing shareholder dilution.

Notable Investors

Information about individual investors or institutional backers is not publicly available.

Utilization of Capital

The capital raised is primarily allocated towards advancing the clinical development of MIRA Pharmaceuticals' lead product candidate, Ketamir-2, and supporting the company's operational expenses.

Pipeline Development

Key Pipeline Candidates

Ketamir-2: A novel, patent-pending oral ketamine analog under investigation for the treatment of neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

MIRA-55: An oral pharmaceutical marijuana analog being developed for the treatment of anxiety and cognitive decline associated with early-stage dementia.

Stages of Clinical Trials

Ketamir-2: The company has initiated Phase 1 clinical trials for Ketamir-2, focusing on assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in humans.

MIRA-55: Development is in the preclinical stage, with plans to advance into clinical trials pending regulatory approvals.

Target Conditions

Ketamir-2: Neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

MIRA-55: Anxiety and cognitive decline associated with early-stage dementia.

Anticipated Milestones

Ketamir-2: Completion of Phase 1 trials and progression to Phase 2 studies are anticipated in the near future, contingent upon successful outcomes and regulatory approvals.

MIRA-55: Advancement into clinical trials is planned, with timelines dependent on preclinical results and regulatory processes.

Technological Platform and Innovation

Proprietary Technologies

MIRA Pharmaceuticals has developed proprietary formulations of existing compounds, such as Ketamir-2, to enhance therapeutic efficacy and safety profiles.

Significant Scientific Methods

The company employs advanced pharmacokinetic modeling and formulation techniques to optimize drug delivery and therapeutic outcomes.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, MIRA Pharmaceuticals is committed to integrating innovative technologies to advance its drug development processes.

Leadership Team

Executive Profiles

Erez Aminov: Chief Executive Officer and Chairman. Brings extensive experience in pharmaceutical development and corporate leadership, steering the company's strategic direction and operations.

Alan Weichselbaum, CPA, M.B.A.: Chief Financial Officer. Provides financial oversight and strategic financial planning, leveraging his expertise in accounting and business administration.

Dr. Itzchak Angel, Ph.D.: Chief Scientific Advisor. Offers scientific guidance and expertise, contributing to the advancement of the company's research and development initiatives.

Competitor Profile

Market Insights and Dynamics

The pharmaceutical industry, particularly in the neuroscience sector, is characterized by rapid innovation and significant competition. Companies strive to develop effective treatments for complex conditions, navigating regulatory challenges and market dynamics.

Competitor Analysis

AstraZeneca plc: A global leader in pharmaceuticals, competing in the development of innovative treatments across various therapeutic areas, including oncology and respiratory diseases.

Biogen Inc.: Specializes in neurology, offering treatments for neurological diseases such as multiple sclerosis and Alzheimer's, presenting competition in the neurology sector.

Gilead Sciences, Inc.: Focuses on antiviral and cancer therapies, with a robust pipeline and extensive market reach, posing competition in specialty pharmaceuticals.

Regeneron Pharmaceuticals, Inc.: Known for its advanced biopharmaceutical research, competing in areas such as eye diseases and oncology.

Vertex Pharmaceuticals Incorporated: Specializes in cystic fibrosis treatments, with a strong reputation in developing highly effective therapies.

Strategic Collaborations and Partnerships

MIRA Pharmaceuticals has engaged in strategic collaborations to enhance its development capabilities, including a proposed acquisition of SKNY Pharmaceuticals to expand its pipeline.

Operational Insights

MIRA Pharmaceuticals operates in a competitive landscape, focusing on differentiating its products through innovative formulations and targeted therapies to address unmet needs in the market.

Strategic Opportunities and Future Directions

The company aims to advance its pipeline through successful clinical trials, strategic partnerships, and potential acquisitions, positioning itself to achieve future objectives in the pharmaceutical industry.